AMGEN INC.
(NASDAQ:AMGN)
Balfour Capital Group has issued a buy recommendation for Amgen Inc. (AMGN) on September 5th, 2023.
Amgen Inc., established in 1980, is a leading biotechnology company dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas such as oncology, inflammation, general medicine, and rare diseases, aiming to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $256.71 on September 5th, 2023.
- Our designated price target stands at $350.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Amgen Inc. (AMGN)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
